600664.SH
Harbin Pharmaceutical Group Co., Ltd.
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 5.40
+1.89%Year over year
Reported trailing growth
- Revenue
- -1.5%
- EBITDA
- —
- EBIT
- -43.1%
- EPS
- -54.7%
- Free cash flow
- +14.9%
- Operating cash flow
- +19.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- -5.4%
- EBIT
- -5.6%
- Net income
- -8.1%
- EPS
- -9.7%
- Free cash flow
- -18.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026